IL6 and ovarian carcinoma: Collectively, these findings demonstrate that loss of SHMT1 results in decreased expression of the pro-oncogenic inflammatory cytokines IL-6 and IL-8, which in turn results in inhibition of ovarian cancer tumor growth.